Dr. Henry Ji to Participate in Multiple Investment Conferences in September 2019 to Provide Corporate Updates

SAN DIEGO, Sept. 05, 2019 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. SRNE ", Sorrento", ))), announced today that Dr. Henry Ji, Chairman and CEO, will participate in multiple investment conferences in September 2019. Dr. Ji will provide corporate updates to investors, focusing on the core clinical pipeline progress for Sorrento Therapeutics immuno-oncology and pain programs.

Details of the upcoming events:

Bio Century Newsmakers in the Biotech Industry
Date: Friday, September 6^th
Time: 10:40 AM Eastern Time
Location: Millennium Broadway Hotel
Times Square Room 404/405, NY
Webcast: http://media.rampard.com/newsmakers/sorrentotherapeutics

21^st Annual Global Investment Conference Sponsored by H.C. Wainwright
Date: Tuesday, September 10^th
Time: 10:50 AM Eastern Time
Location: Lotte New York Palace, Holmes II (4th Floor), NY
Webcast: http://wsw.com/webcast/hcw5/srne/

Rambam Foundation Healthcare Conference
Topic: Off the shelf cellular therapies
Date: Tuesday, September 10^th
Time: 12:30 PM Eastern Time
Location: The Mansion: 107 E 16th NY

About Sorrento Therapeutics, Inc. 

Sorrento is a clinical stage, antibody-centric, biopharmaceutical company developing new therapies to turn malignant cancers into manageable and possibly curable diseases. Sorrento's multimodal multipronged approach to fighting cancer is made possible by its' extensive immuno-oncology platforms, including key assets such as fully human antibodies ("G-MAB™ library"), antibody-drug conjugates ("ADC") as well CAR-T and oncolytic virus ("Seprehvir^®"). 

Sorrento's commitment to life-enhancing therapies for cancer patients is also demonstrated by our effort to advance a first-in-class (TRPV1 agonist) RTX and ZTlido^®. RTX is completing a phase IB trial in terminal cancer patients. ZTlido^® was approved by US FDA on February 28, 2018.

For more information visit www.sorrentotherapeutics.com

Forward-Looking Statements

This press release and any statements made for and during any presentation or meeting contain forward-looking statements related to Sorrento Therapeutics, Inc. under the safe harbor provisions of Section 21E of the Private Securities Litigation Reform Act of 1995 and subject to risks and uncertainties that could cause actual results to differ materially from those projected. Forward looking statements include statements regarding the developments of and prospects for Sorrento's and its subsidiaries' and affiliates' products and technologies, including any financings and expected uses of the proceeds from such financings; expected clinical trials, non-dilutive financing opportunities based on clinical data readouts and Sorrento's M&A and licensing strategy. Risks and uncertainties that could cause our actual results to differ materially and adversely from those expressed in our forward-looking statements, include, but are not limited to: risks related to Sorrento's, its subsidiaries', affiliates' and partners' technologies and prospects; clinical development risks, including risks in the progress, timing, cost, and results of clinical trials and product development programs; risk of difficulties or delays in obtaining regulatory approvals; risks that clinical study results may not meet any or all endpoints of a clinical study and that any data generated from such studies may not support a regulatory submission or approval; risks related to seeking regulatory approvals and conducting clinical trials; risks of supplying drug product; risks related to leveraging the expertise of its employees, subsidiaries, affiliates and partners to assist the company in the execution of its strategies; risks related to Sorrento's debt obligations; and other matters that are described in Sorrento's Annual Report on Form 10-K for the year ended December 31, 2018, and subsequent Quarterly Reports on Form 10-Q filed with the Securities and Exchange Commission, including the risk factors set forth in those filings. Investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this release and we undertake no obligation to update any forward-looking statement in this press release except as required by law.

Media and Investor Relations

Contact: Alexis Nahama, DVM (VP Corporate Development)

Telephone: 1.858.203.4120

Email: mediarelations@sorrentotherapeutics.com

ZTlido^® and G-MAB™ are trademarks owned by Scilex Pharmaceuticals Inc. and Sorrento, respectively.

Seprehvir^®, is a registered trademark of Virttu Biologics Limited, a wholly-owned subsidiary of TNK Therapeutics, Inc. and part of the group of companies owned by Sorrento Therapeutics, Inc.

All other trademarks are the property of their respective owners.

© 2019 Sorrento Therapeutics, Inc. All Rights Reserved.